Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

663
Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
663
Retrovirus Life Cycles01:10

Retrovirus Life Cycles

48.4K
Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the...
48.4K
Viral Mutations00:36

Viral Mutations

37.3K
A mutation is a change in the sequence of bases of DNA or RNA in a genome. Some mutations occur during replication of the genome due to errors made by the polymerase enzymes that replicate DNA or RNA. Unlike DNA polymerase, RNA polymerase is prone to errors because it is not capable of “proofreading” its work. Viruses with RNA-based genomes, like HIV, therefore accrue mutations faster than viruses with DNA-based genomes. Because mutation and recombination provide the raw material...
37.3K
Vaccinations01:51

Vaccinations

49.2K
Overview
49.2K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs.

Journal of virology·2024
Same author

Microsecond dynamics control the HIV-1 Envelope conformation.

Science advances·2024
Same author

Discovery and Characterization of a Pan-betacoronavirus S2-binding antibody.

bioRxiv : the preprint server for biology·2024
Same author

Broadly neutralizing antibody induction by non-stabilized SARS-CoV-2 Spike mRNA vaccination in nonhuman primates.

bioRxiv : the preprint server for biology·2024
Same author

Vaccine induction of CD4-mimicking HIV-1 broadly neutralizing antibody precursors in macaques.

Cell·2024
Same author

Engineering immunogens that select for specific mutations in HIV broadly neutralizing antibodies.

bioRxiv : the preprint server for biology·2024

Related Experiment Video

Updated: Nov 18, 2025

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.1K

HIV mRNA Vaccines-Progress and Future Paths.

Zekun Mu1,2, Barton F Haynes1,2, Derek W Cain1

  • 1Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA.

Vaccines
|February 10, 2021
PubMed
Summary
This summary is machine-generated.

Messenger RNA (mRNA) vaccines, delivered via lipid nanoparticles (LNPs), offer a novel approach for generating immune responses. This review explores mRNA vaccine strategies for developing effective HIV vaccines.

Keywords:
HIVmessenger RNAvaccine

More Related Videos

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.8K
Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

11.6K

Related Experiment Videos

Last Updated: Nov 18, 2025

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy
12:03

Evaluation of the Efficacy And Toxicity of RNAs Targeting HIV-1 Production for Use in Gene or Drug Therapy

Published on: September 5, 2016

8.1K
Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation
10:58

Production of E. coli-expressed Self-Assembling Protein Nanoparticles for Vaccines Requiring Trimeric Epitope Presentation

Published on: August 21, 2019

7.8K
Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase
10:20

Interview: HIV-1 Proviral DNA Excision Using an Evolved Recombinase

Published on: June 16, 2008

11.6K

Area of Science:

  • Vaccinology
  • Immunology
  • Molecular Biology

Background:

  • The COVID-19 pandemic highlighted the potential of mRNA vaccines encapsulated in lipid nanoparticles (LNPs).
  • mRNA vaccines leverage host cells to produce immunogens, stimulating antibody and T cell responses.
  • mRNA vaccine technology has been researched for over 30 years for various diseases, including cancers and infectious diseases.

Purpose of the Study:

  • To review mRNA-based vaccine approaches for prophylactic and therapeutic HIV vaccination.
  • To examine the immunological challenges in developing an effective HIV vaccine.
  • To propose an mRNA-based HIV vaccination strategy informed by broadly neutralizing antibody development.

Main Methods:

  • Literature review of mRNA vaccine technology.
  • Analysis of immunological hurdles specific to HIV vaccine development.
  • Discussion of immunobiology related to broadly neutralizing antibodies.

Main Results:

  • mRNA vaccines represent a promising platform for HIV vaccine development.
  • Overcoming immunological barriers is critical for eliciting broadly neutralizing antibodies and effective T cell responses against HIV.
  • Understanding the immunobiology of antibody development can guide effective mRNA vaccine design.

Conclusions:

  • mRNA technology offers a flexible platform for developing novel HIV vaccines.
  • Targeted strategies are needed to address the unique immunological challenges of HIV.
  • Further research into mRNA-based HIV vaccination strategies is warranted.